In the Fall 2006, Nura was acquired by Omeros Corporation,. A development stage biotechnology company, Nura organizes around discovery of therapeutics for behavioral disorders and neurodegenerative diseases with a focus on behavioral and neurodegenerative diseases with particular emphasis on G Protein-coupled receptor (GPCR) and phosphodiesterase (PDE) targets expressed in the brain: nuerodegenerative diseases, such as Parkinson's and Alzheimer's diseases, and behavioral disorders, such as depression, anxiety, schizophrenia, obesity and addiction
